［1］Went P,Agostinelli C,Gallamini A,et al.Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score［J］.J Clin Oncol,2006,24(16):2472-2479.
［2］Vose J,Armitage J,Weisenburger D.International T-cell lymphoma project international peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes［J］.J Clin Oncol,2008,26:4124-4130.
［3］de Leval L,Gisselbrecht C,Gaulard P.Advances in the understanding and management of angioimmunoblastic T-cell lymphoma［J］.Br J Haematol,2010,148:673-689.
［4］Federico M,Rudiger T,Bellei M,et al.Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma:analysis of the international peripheral T-cell lymphoma project［J］.J Clin Oncol,2013,31:240-246.
［5］Kim CH,Lim HW,Kim JR,et al.Unique gene expression program of human germinal center T helper cells［J］.Blood,2004,104:1952-1960.
［6］Yu H，Shahsafaei A，Dorfman DM Germinal．Center T-helper-cell markers PD-1 and CXCLl3 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma［J］．Am J Clin Pathol，2009，131：33-41．
［7］Murakami YI，Yatabe Y，Sakaguchi T，et al．C-Maf expression in angioimmunoblastic T-cell lymphoma［J］．Am J Surg Pathol，2007，31：1695-1702．
［8］Mamiko SY,Terukazu Enami. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma［J］.Nature Genetics,2014,46:171-175.
［9］Schmitz N，Trümper L，Ziepert M，et al．Treatment and prognosis of mature T-cell and NK-cell lymphoma：an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group［J］．Blood,2010,116：3418-3425．
［10］Vokurka S，Koza V，Vozobulová V，et al．Angioimmunoblastic T-cell lymphoma as a very poor-prognosis malignancy-a single centre experience［J］．Klin Onkol，2012，25(3)：206-211．
［11］Mourad N，Mounier N，Brière J，et al．Clinical，biologic，and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des lymphomes de l'Adulte(GELA)trials［J］．Blood，2008，111(9)：4463-4470．
［12］Zhao S，Zhang L,Zhang M,et al．Anginimmunoblastic T-cell lymphoma：the effect of initial treatment and microvascular density in 31 patients［J］．Med Oncol,2012,29：2311-2316．
［13］Dueck G，Chua N,Prasad A，el al.Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma［J］．Cancer，2010，116：4541-4548．
［14］Ramasamy K，Lim Z，Pagliuca A,et al．Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone［J］．Haematologica，2006，91(8 Suppl)：ECR44．
［15］Aguiar Bujanda D．Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab［J］．Ann Oncol，2008，19(2)：396-397．
［16］Wang L，Shi WY，Yang F，et al．Bevacizumab potentiates chemotherapeutic effect on T-leukemia／lymphoma cells by direct action on tumor endothelial cells［J］．Haematologica，2011，96(6)：927-931．
［17］Gallamini A,Zaja F,Patti C,et al.Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma:results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial［J］.Blood,2007,110:2316.
［18］Kim J,Sohn S,Chae Y,et al.Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas:a phase II study［J］.Cancer Chemother Pharmacol,2007,60(1):129-134.
［19］D'Amore F,Radford J,Relander T,et al.Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma［J］.Br J Haematol,2010,150:565-573.
［20］Numata A，Miyamoto T，Ohno Y,et al.Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma：retrospective analysis of the experience of the Fukuoka BMT group［J］．Bone Marrow Transplant，2010，45：311-316．
［21］Kyriakou C,Canals C,Goldstone A,et al.High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma:complete remission at transplantation is the major determinant of outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation［J］.J Clin Oncol,2008,26:218-224.
［22］Schetelig J,Fetscher S,Reichle A,et al.Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation［J］.Haematologica,2003,88:1272-1286.
［23］Amore F,Relander T,Lauritzsen GF.Up-front autologous stem - cell transplantation in peripheral T-cell lymphoma:NLG-T-01［J］.J Clin Oncol,2012,30:3093-3099.
［24］Kyriakou C,Canals C,Finke J,et al.Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma:a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation［J］.J Clin Oncol,2009,27:3951-3958.
［25］O'Connor OA,Pro B,Brown LP,et al.Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma:results from the pivotal PROPEL study［J］.J Clin Oncol,2011,29:1182-1189.
［26］Piekarz RL,Frye R,Prince HM,et al.Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma［J］.Blood,2011,117:5827-5834.
［27］Horowitz S.Oral presentations［J］.Hematol Oncology,2013,31(S1):96-150.
［28］Larue M.Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma.A clinicobiological study of the GELA［J］.Haematologica,2011,97:1594-1602.
［29］Kim SJ,Yoon DH,Kang HJ,et al.Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas:a multicentre,single-arm,phase 2 trial［J］.Eur J Cancer,2012,48:3223-3231.
［30］Delmer A,Fitoussi O,Gaulard P,et al.A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma:results of the GELA LNH05-1T trial［J］.J Clinl Oncol,2009,27(15):12.
［31］Dang NH,Pro B,Hagemeister FB,et al.Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma［J］.Br J Haematol,2007,136:439-447.
［32］Foss,Francine M,Nelida Sjak-Shie,et al.A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide,doxorubicin,vincristine and prednisone in untreated peripheral T-cell lymphoma:the CONCEPT study［J］.Leukemia & Lymphoma,2013,54(7):1373-1379.